Market

Receives approval from US FDA

M&A activity in the pharmaceutical sector was focused on advancing the development of promising products through complementary…

Organised by Infinity Business Services and supported by I3R Global, the conference aimed to highlight the latest trends and…

The blockbuster model has so far been the success formula of pharma companies, however, if statistics are to be believed, a churn…

Infectious diseases continue to account for majority of the disease burden in developing countries even as they grapple with an…

Is indicated for the treatment of anaemia caused due to chronic kidney disease

Abbott will acquire the holding company that indirectly owns approximately 73 per cent of CFR Pharmaceuticals

Mersana and Merck Serono will leverage Mersana’s Fleximer technology to generate ADCs for multiple undisclosed targets

To launch new drugs for treating Type-II diabetes, depression and coronary heart diseases

11 therapies have outgrown the IPM growth and five therapies have double digit growths